On a blustery day last December, five biotech entrepreneurs and scientists walked past the snow-draped Boston Common and entered Yvonne’s, the cozy supper club and bar, to discuss a new potential biotechnology company to fight cancer.

There, over libations poured at a mahogany bar, they talked about the recent success of groundbreaking drugs that harness the immune system to combat cancers of the blood. Could they do something similar to treat solid tumors, which are far more common? Could they use “natural killer” cells, a potent immunological weapon that can be harvested from healthy people? If so, what would be the best approach?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]